The Brien Holden Vision Institute’s Professor Padmaja Sankaridurg has presented trial data on the Essilor Stellest lens for myopia control, as the company behind the lens revealed new conclusive three-year data.
In a global statement on 7 September, EssilorLuxottica released the much-anticipated three-year clinical trial results of the Essilor Stellest spectacle lens, showing the lens continued to exhibit strong efficacy in slowing myopia progression and axial elongation in the third year.
It was reported at the International Myopia Conference (IMC) 2022 in Rotterdam, Netherlands, in a plenary talk by EssilorLuxottica research and development expert Dr Björn Drobe.
The clinical trial was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China, where 151 children from the first two years of the study were switched to spectacle lenses with highly aspherical lenslets (HAL) while a new set of 56 children were recruited and wore single vision lenses.
According to EssilorLuxottica, key highlights from the clinical trial included:
- Essilor Stellest lenses saved more than one diopter of myopia on average over three years, demonstrating conclusive evidence that they remain effective in slowing down myopia progression in children in the third year.1
- The results confirmed the significant positive impact of wearing time on myopia control efficacy. Children who wore Essilor Stellest lenses full time2 saw a marked increase in myopia control efficacy.
- Aside from being effective in younger children, the results confirm that the Essilor Stellest lenses are also effective in slowing myopia progression and axial elongation in older children.
During IMC, EssilorLuxottica’s satellite session was facilitated by Dr. Mark A. Bullimore, from the University of Houston, College of Optometry Professor, and Ms Olga Prenat, head of medical marketing, professional relations and vision care education at EssilorLuxottica.
A session titled ‘Essilor Stellest lens – New benefits of myopia control spectacle lenses’ saw presentations from EssilorLuxottica’s research and development experts, Dr Damien Paillé and Drobe.
The session also had presentations from Professor Padmaja Sankaridurg, head of BHVI’s Myopia Program, titled ‘Essilor Stellest lens: Results from a randomised, double-blind, cross-over clinical trial’, and from Bullimore on the impact of spectacle lenses for myopia control on visual function, and myopia control in other ethnicities.
Mr Norbert Gorny, co-chief operating officer at EssilorLuxottica, said the company was “extremely encouraged” to have such conclusive data showing that Essilor Stellest lenses continued to slow down myopia progression in children after three years.
“With the growing prevalence of myopia and associated risk of ocular conditions, we are proud to be at the forefront of myopia management with our lenses to move the needle in the fight against myopia,” he said.
“The lens is now available in more than 20 countries, and we will continue to expand our footprint in the future and help advance knowledge and education of myopia management to ensure that everyone understands the importance and benefits of managing myopia early and proactively in children.”
More reading
EssilorLuxottica unification takes shape in ANZ
Mark Zuckerberg teases new EssilorLuxottica smart glasses with neural interface
‘Life-proof’ lens coating technology
References
- Compared to SVL (0-24months) + SVL2 (24 – 30 months) progression. SVL2 was the new control group of 56 children, especially recruited for the 3rd year and fitted with single vision lenses.
- Children who wore the spectacles ≥ 12h/day, everyday
